Funding
Grant · Biotech

EpiFrontier Therapeutics receives $32m AMED grant

The Japan Agency for Medical Research and Development provided grant funding to the beta-globin therapeutics developer.

Updated Oct 16, 2026By RoundOS Funding desk

EpiFrontier Therapeutics received $32 million in grant funding from the Japan Agency for Medical Research and Development on March 24. The company develops therapies for beta-globin disorders.

Funding history

Grant · This round$32M

Sources

  1. EpiFrontier Therapeuticsprojectstartups.com
  2. prnewswire.com

Similar rounds

All Biotech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Warp Sciences

Warp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States.

$215MSeries A · Oct 22, 2026

Related